

Table 1 Schedule of assessments and screening for durvalumab + EP treatment

	Screening	During Chemotherapy 1 cycle = 3 weeks (21 days) ^a					Post Chemotherapy 1 cycle = 4 weeks (28 days)	
		C1	C2	C3	C4	C5 and C6 ^a	C7 to PD	
Visit Window	Day -28 to Day -1	0	±3 days unless dosing needs to be held for toxicity reasons					
Week	Weeks -4 to Week -1	0	3	6	9	12 ^a	15 ^a	q4w
								For details, see Section
Informed Consent								
Informed consent: study procedures ^b	X							5.1
CCI	X							5.1
Study procedures								
Physical exam (full)	X							8.2.2
Targeted physical exam ^c		X	X	X	X	X	X	8.2.2
Medical history ^d	X							
Vital signs ^e	X	X	X	X	X	X	X	8.2.3
ECG ^f	X	As clinically indicated						8.2.4
Concomitant medications		<----->						6.4
Demography, including baseline characteristics and tobacco use	X							5.1
Eligibility criteria	X	X						5.1, 5.2
Laboratory Assessments								
Clinical chemistry ^g	X	X ^h	X	X	X	X	X	Table 9
Hematology ^g	X	X ^h	X	X	X	X	X	Table 10
Coagulation ⁱ		X						Table 10
TSH ^j , (reflex free T3 or free T4 ^k)	X	X	X	X	X	X	X	Table 9
Urinalysis	X	As clinically indicated						Table 11
Hepatitis B and C and HIV	X							8.2.7
Pregnancy test ^l	X	X	X	X	X	X	X	8.2.1
Monitoring								
WHO/ECOG performance status	X	X	X	X	X	X	X	8.2.5
AE/SAE assessment ^m		<----->						8.3
Assessment of early toxicities (phone call) ⁿ		X	X	X				8.2.5